Biotech Values

[DewDiligence]

BAX/ELN/PFE/JNJ: The worst case for BAX—assuming Gammagard for AD ends up reaching the market—is having to pay a single-digit-% royalty for the patent in question, IMO. Even then, PFE/JNJ/ELN will have a tough time collecting in full insofar as the Gammagard product for existing indications will likely be indistinguishable from the Gammagard product for AD.

p.s. It sounds like ‘agedwardssucks’ considers ELN a world-class screw-up. All told, it’s hard to disagree.